Log in to search using one of your social media accounts:

 

NxStage shares dip on Q3 EPS miss
Shares in NxStage Medical (NSDQ:NXTM) have fallen slightly today after the medical device maker missed expectations on Wall Street with its third quarter earnings results. The Lawrence, Mass.-based company posted losses of $8.9 million, or 14¢ per share, on sales of $97.3 million for the 3 months ended September 30, seeing losses grow nearly 900% while sales grew a smaller 5.8% compared with the same period during the previous fiscal year, according to an SEC filing. Losses per share were well ahead of Wall Street analysts’ consensus, who expected to see the company break even. The company did not issue a r...
Source: Mass Device - November 22, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News MassDevice Earnings Roundup NxStage Medical Inc. Source Type: news

Despite stormy quarter, Medtronic earnings beat Wall Street estimates
Medical-device giant Medtronic reported profits that beat Wall Street expectations Tuesday despite battling hurricanes and wildfires during its most recent quarter. The company’s adjusted second-quarter earnings totaled $1.46 billion, or $1.07 per share. That’s down from $1.56 billion, or $1.12 per share, but better than analysts’ estimated 98 cents per share. The company’s stock rose about 5 percent to $83.07 per share in afternoon trading Tuesday. Hurricane Maria ultimately cost Medtronic… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - November 21, 2017 Category: Pharmaceuticals Authors: Katharine Grayson Source Type: news

Despite stormy quarter, Medtronic earnings beat Wall Street estimates
Medical-device giant Medtronic reported profits that beat Wall Street expectations Tuesday despite battling hurricanes and wildfires during its most recent quarter. The company’s adjusted second-quarter earnings totaled $1.46 billion, or $1.07 per share. That’s down from $1.56 billion, or $1.12 per share, but better than analysts’ estimated 98 cents per share. The company’s stock rose about 5 percent to $83.07 per share in afternoon trading Tuesday. Hurricane Maria ultimately cost Medtronic… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - November 21, 2017 Category: Biotechnology Authors: Katharine Grayson Source Type: news

Medtronic ’ s fiscal Q2 tops The Street
Medtronic (NYSE:MDT) posted fiscal second-quarter numbers that beat both sales and earnings forecasts on Wall Street, after a better-than-expected recovery from Hurricane Maria. The Fridley, Minn.-based medical device giant reported profits of $2.02 billion, or $1.48 per share, on sales of $7.05 billion for the three months ended Oct. 27, for a bottom-line gain of 80.9% on a -4.0% sales decline compared with the same period last year. Adjusted to exclude one-time items, earnings per share were $1.06, 8¢ ahead of The Street, where analysts were looking for sales of $6.93 billion. “Our second-quarter financial res...
Source: Mass Device - November 21, 2017 Category: Medical Devices Authors: Brad Perriello Tags: MassDevice Earnings Roundup Wall Street Beat Medtronic Source Type: news

UPDATE: Medtronic ’ s fiscal Q2 tops The Street
UPDATED November 21, 2017, with segment results, share prices Medtronic (NYSE:MDT) posted fiscal second-quarter numbers that beat both sales and earnings forecasts on Wall Street, after a better-than-expected recovery from Hurricane Maria. The Fridley, Minn.-based medical device giant reported profits of $2.02 billion, or $1.48 per share, on sales of $7.05 billion for the three months ended Oct. 27, for a bottom-line gain of 80.9% on a -4.0% sales decline compared with the same period last year. Adjusted to exclude one-time items, earnings per share were $1.06, 8¢ ahead of The Street, where analysts were looking for s...
Source: Mass Device - November 21, 2017 Category: Medical Devices Authors: Brad Perriello Tags: MassDevice Earnings Roundup Wall Street Beat Medtronic Source Type: news

LivaNova to deal CRM biz to MicroPort for $190m
LivaNova (NSDQ:LIVN) said today that it inked a deal to sell its cardiac rhythm management business to China’s MicroPort Scientific (HK:00853) for $190 million in cash. The companies, which are already partners in a CRM join venture in the People’s Republic, said the sale for LivaNova’s 900-worker CRM business is slated to close during the second quarter next year. LivaNova, formed by the $2.7 billion merger of Italy’s Sorin and Cyberonics in October 2015, said in September that it was putting the CRM business on the auction block. The business pulled in sales of $249 m...
Source: Mass Device - November 20, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Mergers & Acquisitions Wall Street Beat Cardiac Rhythm Management LivaNova MicroPort Scientific Source Type: news

Is There Hope for an Endologix Comeback?
A year ago, Endologix CEO John McDermott walked into the VEITHsymposium at the New York Hilton-Midtown, saw the look on the face of his head of regulatory and clinical affairs as he approached the Endologix booth, and knew something was wrong. Sure enough, FDA had just asked Endologix to provide two-year patient follow-up data from its EVAS-FORWARD study of the Nellix endovascular aneurysm sealing (EVAS) system. "So that night we worked through the night to get out our press release first thing the next morning to inform the world that there was going to be pushback in the timeline and the clinical requirements,&...
Source: MDDI - November 19, 2017 Category: Medical Devices Authors: Amanda Pedersen Tags: Medical Device Business Source Type: news

HMSA reports $14.6M profit for Q3
The Hawaii Medical Service Association reported net income of $14.6 million for the third quarter 2017, down 17.9 percent from last year's third quarter earnings of $17.8 million. The company said its net gain, which came from rebalancing its investment portfolio, will go into the HMSA reserve and maintain financial security for the health plan’s members. “Our reserve provides peace of mind for our members, employers, and doctors and hospitals. It ensures that funds ar e always available to… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - November 17, 2017 Category: American Health Authors: Anna Hrushka Source Type: news

Shares in Delcath fall after losses grow in Q3
Shares in Delcath Systems (NSDQ:DCTHD) crashed today after the company posted its third quarter results, revealing that the company’s net losses have grown dramatically quarter-over-quarter. The N.Y.-based company posted a net loss of -$12.6 million on sales of $684,000 for the 3 months ended Sept. 30, for sales growth of 57% compared with the same period last year. In Q3 of last year, Delcath posted a net loss of just -$1.0 million. Get the full story at our sister site, Drug Delivery Business News. The post Shares in Delcath fall after losses grow in Q3 appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - November 16, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations MassDevice Earnings Roundup Oncology Pharmaceuticals Wall Street Beat Delcath Systems Inc. Source Type: news

Teleflex announces upcoming $500m senior note offering
Teleflex (NYSE:TFX) today announced a new public offering of senior notes due 2027, looking to raise approximately $500 million. The Wayne, Penn.-based company has not yet released prices of the notes, and said that the interest rates and other terms will be determined at pricing. Teleflex said that net proceeds from the round will be used to repay approxiamtely $491.2 million in debt borrowings under its revolving credit facility, according to a press release. J.P. Morgan, Bank of America Merrill Lynch and PNC Capital Markets will act as joint book-running managers in the offering, the company said. Earlier this mont...
Source: Mass Device - November 16, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Teleflex Source Type: news

Merit Medical to pay $100m for Bard, BD biopsy assets
Merit Medical (NSDQ:MMSI) said today that it agreed to pay $100 million for soft tissue biopsy assets Becton Dickinson (NYSE:BDX) and C.R. Bard (NYSE:BCR) need to sell to consummate their $24 billion merger. The deal covers BD’s Achieve and Temno biopsy systems and Tru-Cut biopsy needles, plus Bard’s Aspira pleural effusion drainage and peritoneal drainage systems, South Jordan, Utah-based Merit said. “We believe this is a perfect fit for Merit,” chairman & CEO Fred Lampropoulos said in prepared remarks. “These products are well established with an instal...
Source: Mass Device - November 16, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Mergers & Acquisitions Wall Street Beat Source Type: news

Pavmed shares climb after Q3 EPS beat
Shares in Pavmed Inc. (NSDQ:PAVM) rose today after the medical device maker beat expectations on Wall Street with its third quarter results. The N.Y.-based company posted a net loss of -$5.37 million, or -40¢ per share, for the 3 months ended Sept. 30, for bottom-line loss of -178.5% compared with the same period last year. Get the full story at our sister site, Drug Delivery Business News. The post Pavmed shares climb after Q3 EPS beat appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - November 15, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations MassDevice Earnings Roundup Otolaryngology Ear, Nose & Throat Pharmaceuticals Regulatory/Compliance Research & Development Wall Street Beat Pavmed Source Type: news

Mount Sinai Medical Center takes loss in third quarter
Patient admissions and surgeries declined in the aftermath of Hurricane Irma. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - November 15, 2017 Category: American Health Authors: Brian Bandell Source Type: news

GE to refocus on healthcare, other select divisions
GE  (NYSE:GE) said this week it aims to narrow its business focus to healthcare, power and aviation, according to a Reuters report. The move comes as part of a maneuver the company hopes will center it behind the businesses with the most growth potential. GE will also focus on sectors where it has innovative technology, appropriate scale and a large base of installed customers, according to the report. The conglomerate set an earnings target of between $1.00 and $1.07 for the next year, down from an earlier forecast, Reuters reports. The company will also look to cut its board size from 18 to 12 members, with 3 n...
Source: Mass Device - November 15, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News General Electric Source Type: news

Neovasc shares fall on Q3 sales miss
Shares in Neovasc (NSDQ:NVCN) have risen in early morning trading today after the medical device maker posted 2nd quarter earnings that beat the Street on losses per share but missed on sales. The Vancouver-based company posted losses of $5.8 million, or 6¢ per share, on sales of $1.4 million for the 3 months ended September 30, seeing losses shrink 79.9% while sales were reduced 54.7% compared with the same period last year. Losses per share were just ahead of the 7¢ per share consensus on Wall Street, though sales fell well short of the Street’s $1.8 million expectations. “From a product perspe...
Source: Mass Device - November 15, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News MassDevice Earnings Roundup Neovasc Inc. Source Type: news

Avinger slashes jobs, Q3 sales down 61%
Avinger (Nasdaq:AVGR) – maker of the Lumivascular image-guided, catheter-based system to treat peripheral artery disease (PAD) – continued to experience declining sales as it retrenched during the third quarter, according to its newest earnings report. The Redwood, Calif.–based company has been cutting jobs and other costs– and focusing on existing accounts and winning FDA clearance for new devices. Avinger had 73 employees, including 20 sales employees, as of Oct. 15. The number is down nearly two-thirds from the 197 employees, including 70 in sales, that the company had at the end of 201...
Source: Mass Device - November 13, 2017 Category: Medical Devices Authors: Chris Newmarker Tags: Business/Financial News Cardiovascular Catheters Imaging News Well Avinger Source Type: news

GI Dynamics loses CE Mark certificate for EndoBarrier
GI Dynamics (ASX:GID) said yesterday that its notified body in Europe withdrew its certification for CE Mark approval for its EndoBarrier device, meaning the company can no longer sell the obesity and diabetes treatment in the European Union. CEO Scott Schorer told MassDevice.com today during a telephone interview that Boston-based GID passed an intensive, week-long inspection of its quality management system and was taken by surprise when SGS United Kingdom said Nov. 11 that it would withdraw the CE Mark effective Nov. 12. When the potential CE Mark suspension was announced in May the company said it would have ...
Source: Mass Device - November 13, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Diabetes Regulatory/Compliance Weight loss GI Dynamics Source Type: news

Globus Medical shares rise on Q3 beat
Shares in Globus Medical (NYSE:GMED) rose today after the medical device maker beat expectations on Wall Street with its 3rd quarter earnings results. The Audubon, Penn.-based company posted profits of $25.6 million, or 26¢ per share on sales of $151.7 million for the 3 months ended September 30, seeing the bottom line shrink 2.4% while sales grew 11.9% compared with the same period last year. Adjusted to exclude 1-time items, earnings per share were 30¢, just in line with consensus on Wall Street where analysts were expecting to see revenue of $150.4 million. “We are very pleased with our third quarte...
Source: Mass Device - November 9, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News MassDevice Earnings Roundup Globus Medical Source Type: news

Shares in Titan Pharmaceuticals fall after Q3 miss
Shares in Titan Pharmaceuticals (NSDQ:TTNP) fell today after the company missed expectations on Wall Street with its third quarter results. The San Francisco, Calif.-based company posted a net loss of -$4.2 million on sales of $40,000 for the 3 months ended Sept. 30, for bottom-line loss of -60% on sales growth of 53.8% compared with the same period last year. Get the full story at our sister site, Drug Delivery Business News. The post Shares in Titan Pharmaceuticals fall after Q3 miss appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - November 9, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations MassDevice Earnings Roundup Pain Management Pharmaceuticals Wall Street Beat Titan Pharmaceuticals Source Type: news

Aerie Pharmaceuticals misses EPS estimates by 7 cents in Q3
Shares in Aerie Pharmaceuticals (NSDQ:AERI) fell slightly today after the company missed earnings expectations on Wall Street with its third quarter results. The Irvine, Calif.-based company posted a net loss of -$32.4 million, or -89¢ per share, for the 3 months ended Sept. 30, for bottom-line loss of -36% compared with the same period last year. Get the full story at our sister site, Drug Delivery Business News. The post Aerie Pharmaceuticals misses EPS estimates by 7 cents in Q3 appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - November 9, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations MassDevice Earnings Roundup Optical/Ophthalmic Pharmaceuticals Wall Street Beat Aerie Pharmaceuticals Source Type: news

Hologic shares steady on Q4, FY2017 earnings beat
Shares in Hologic (NSDQ:HOLX) have stayed steady today after the medical device maker posted fourth quarter and full fiscal year 2017 earnings that topped expectations on Wall Street. For the fourth quarter, the Marlborough, Mass.-based company posted profits of $82.7 million, or 29¢ per share, on sales of $802.9 million for the 3 months ended September 30, seeing the bottom-line shrink 10.3% while sales grew 10.5% compared to the same period during the previous fiscal year. After adjusting to exclude 1-time items, earnings per share were 50¢, just ahead of the 49¢ consensus on Wall Street where an...
Source: Mass Device - November 9, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News MassDevice Earnings Roundup Hologic Source Type: news

Glaukos shares fall despite Q3 beat
Shares in Glaukos (NYSE:GKOS) fell today even though the ophthalmic medical device maker topped expectations on Wall Street with its third quarter results. The San Clemente, Calif.-based company posted profits of $1.3 million on sales of $40.4 million for the 3 months ended Sept.30, for bottom-line growth of 8.3% on sales growth of 36.5% compared with the same period last year. Adjusted to exclude 1-time items, earnings per share were 4¢, ahead of consensus on The Street, where analysts were looking for sales of $39.1 million. “As the pioneer of micro-invasive glaucoma surgery, Glaukos continued i...
Source: Mass Device - November 8, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: MassDevice Earnings Roundup Optical/Ophthalmic Surgical Wall Street Beat Glaukos Source Type: news

Clearside Biomedical misses Q3 earnings estimates
Shares in Clearside Biomedical (NSDQ:CLSD) fell slightly today after the company missed expectations on Wall Street with its third quarter results. The Alpharetta, Ga.-based company posted a net loss of -$18.3 million for the 3 months ended Sept. 30, for bottom-line loss of -226% compared with the same period last year. Get the full story at our sister site, Drug Delivery Business News. The post Clearside Biomedical misses Q3 earnings estimates appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - November 8, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations MassDevice Earnings Roundup Optical/Ophthalmic Pharmaceuticals Wall Street Beat Clearside Biomedical Source Type: news

Regeneron third-quarter profit easily tops Street view on Eylea, Dupixent sales
(Reuters) - Regeneron Pharmaceuticals Inc on Wednesday reported third-quarter profit that sailed past Wall Street estimates on the strength of increased demand for flagship eye treatment Eylea and its new eczema drug Dupixent, boosting its shares almost 7 percent. (Source: Reuters: Health)
Source: Reuters: Health - November 8, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Bellerophon Therapeutics misses EPS estimates in Q3
Shares in Bellerophon Therapeutics (NSDQ:BLPH) fell slightly today after the company missed EPS expectations on Wall Street with its third quarter results. The Warren, N.J.-based company posted a net loss of -$7.6 million for the 3 months ended Sept. 30, for bottom-line loss of -81% compared with the same period last year. Get the full story at our sister site, Drug Delivery Business News. The post Bellerophon Therapeutics misses EPS estimates in Q3 appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - November 8, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations MassDevice Earnings Roundup Respiratory Vascular Wall Street Beat Bellerophon Therapeutics Source Type: news

Surmodics Q4 results top sales, earnings estimates
Shares in Surmodics (NSDQ:SRDX) fell today even though the medical device maker beat expectations on Wall Street with its fourth quarter results. The Eden Prairie, Minn.-based company posted profits of $400,000 on sales of $20.1 million for the 3 months ended Sept. 30, for bottom-line loss of -84.9% on sales growth of 10.4% compared with the same period last year. Get the full story at our sister site, Drug Delivery Business News. The post Surmodics Q4 results top sales, earnings estimates appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - November 8, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations MassDevice Earnings Roundup Pharmaceuticals Wall Street Beat SurModics Inc. Source Type: news

Ocular shares fall on mixed Q3 results
Shares in Ocular Therapeutix (NSDQ:OCUL) fell yesterday after the company beat sales expectations but missed earnings estimates on Wall Street with its third quarter results. The Bedford, Mass.-based company posted a net loss of -$15.6 million on sales of $520,ooo for the 3 months ended Sept. 30, for bottom-line loss of -62% on sales growth of 8.3% compared with the same period last year. Get the full story at our sister site, Drug Delivery Business News. The post Ocular shares fall on mixed Q3 results appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - November 8, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Implants MassDevice Earnings Roundup Pharmaceuticals Wall Street Beat oculartherapeutix Source Type: news

Regeneron profit, revenue beat on Eylea, Dupixent sales
(Reuters) - Regeneron Pharmaceuticals Inc's third-quarter profit and revenue topped analysts' estimates on Wednesday as demand rose for its flagship eye treatment Eylea and its recently launched eczema drug Dupixent. (Source: Reuters: Health)
Source: Reuters: Health - November 8, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Penumbra ’ s Q3 results top estimates
Penumbra (NYSE:PEN) yesterday reported third-quarter results that topped the consensus forecast on Wall Street and raised its sales outlook for the rest of the year, despite a nearly 100% profit slide. The Alameda, Calif.-based medical device company posted profits of $238,000, or 1¢ per share, on sales of $83.9 million for the three months ended Sept. 30, which amounted to a -98.0% bottom-line plunge on sales growth of 24.9% compared with Q3 2016. Analysts on The Street had predicted losses per share of -6¢ on sales of $79.2 million. Penumbra said it now expects to report full-year sales of $324 million to ...
Source: Mass Device - November 8, 2017 Category: Medical Devices Authors: Brad Perriello Tags: MassDevice Earnings Roundup Neurological Wall Street Beat Penumbra Inc. peripheral Source Type: news

Kindred Healthcare stock surges on better-than-expected earnings
Kindred Healthcare Inc. shares rose 40 percent Tuesday after the company's third-quarter earnings report beat analysts' projections. The Louisville-based post-acute and long-term-care provider posted a net loss for the quarter of $95.8 million, or $1.09 per share. Adjusted for continuing core operations, losses totaled 11 cents per share. This beat analysts' projections of a 19 cent per share loss on an adjusted basis, accord ing to Yahoo Finance. For the third quarter of 2016, the company posted… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - November 8, 2017 Category: American Health Authors: Chris Larson Source Type: news

Regeneron's quarterly profit tops estimates on Eylea sales
(Reuters) - Regeneron Pharmaceuticals Inc reported a better-than-expected quarterly profit on Wednesday, helped by higher sales of its flagship eye treatment Eylea. (Source: Reuters: Health)
Source: Reuters: Health - November 8, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Valeant plays down break-up but considers name change
Drugmaker reaffirms full-year profit target as third-quarter beats expectations (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - November 7, 2017 Category: Pharmaceuticals Source Type: news

Nevro shares fall as Q3 losses rise
Shares in Nevro (NYSE:NVRO)  fell today after the medical device maker posted third quarter earnings that saw losses grow over 50%. The Redwood City, Calif.-based company posted losses of $6.2 million, or 21¢ per share, on sales of $82.3 million for the 3 months ended September 30, seeing losses grow 60.3% while sales grew 35% compared with the same period during the prior fiscal year. Losses per share were just below of expectations of 22¢ per share, where analysts were expecting to see sales of $80.5 million for the quarter, which the company also topped. The company lifted its revenue expectations fo...
Source: Mass Device - November 7, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News MassDevice Earnings Roundup nevro Source Type: news

Mazor Robotics crushes expectations with Q3 results
Mazor Robotics (NSDQ:MZOR) today reported third-quarter results that blew past the consensus forecast on Wall Street, more than doubling sales and paring its losses by more than 30%. The Caesarea, Israel-based robot-assisted surgery company posted losses of -$3.7 million, or -7¢ per share, on sales of $17.2 million for the three months ended Sept. 30, cutting red ink by -30.1% on sales growth of 125.4% compared with Q3 2016. Get the full story at our sister site, The Robot Report. The post Mazor Robotics crushes expectations with Q3 results appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - November 7, 2017 Category: Medical Devices Authors: Brad Perriello Tags: MassDevice Earnings Roundup Robotics Wall Street Beat mazorrobotics Source Type: news

Haemonetics to cut 11% of workforce
Haemonetics (NYSE:HAE) said today that it plans to cut roughly 11% of its global workforce as it looks to pare $80 million from its annual cash burn by the end of fiscal 2020. The Braintree, Mass.-based blood management company said it plans to eliminate 350 positions by the end of its fiscal year in April. The company reported employing 3,107 workers as of April 1; a spokeswoman told MassDevice.com this morning that some of the affected positions are already open. Other cuts are in store for direct material and indirect spending, facilities and freight over the next 30 months, the company said. “The w...
Source: Mass Device - November 7, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Blood Management MassDevice Earnings Roundup Wall Street Beat Haemonetics Source Type: news

Henry Schein shares fall on Q3 EPS miss
Shares in Henry Schein (NSDQ:HSIC) have fallen today after the company posted third quarter earnings which beat sales but missed earning per share expectations on Wall Street. The Melville, N.Y.-based company posted profits of $138 million, or 87¢ per share, on sales of $3.2 billion for the 3 months ended September 30, seeing the bottom-line grow 3.2% while sales grew 10.2% compared with the same period last year. Earnings per share didn’t budge after adjusting for 1-time items and sat just below the 89¢ expectations on Wall Street, where analysts expected to see sales of $3.1 billion for the quarter. ...
Source: Mass Device - November 6, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News MassDevice Earnings Roundup Henry Schein Inc. Source Type: news

Grifols wins FDA nod for fibrin sealant
Grifols (NSDQ:GRFS) said this week it won FDA approval for its Fibrin Sealant designed for surgical use in adults. The company said the newly cleared product is composed of the plasma proteins fibrinogen and human thrombin. Grifols said that the Fibrin Sealant will be manufactured at its Parts de Vallés facilities in Barcelona, Spain, according to an SEC filing. Last week, Grifols reported third-quarter sales and earnings growth that missed the consensus forecast The Spanish healthcare giant posted profits of €153.9 million , or €0.22 per share, on sales of €1.06 bil...
Source: Mass Device - November 6, 2017 Category: Medical Devices Authors: Fink Densford Tags: Regulatory/Compliance Surgical Grifols Source Type: news

CVS To Offer Same-Day Prescription Delivery
WOONSOCKET, R.I. (AP) — CVS Health is cranking up prescription deliveries to customer homes or workplaces, as the drugstore chain tries to squeeze more of an edge from a massive store network that puts 70 percent of the U.S. population within three miles of one of its locations. The nation’s second-largest drugstore chain will start offering free, same-day deliveries in December from its Manhattan sites. It will also expand next-day deliveries nationwide early next year while also bringing the same-day service to several more cities. Drugstores and other retailers have been pushing more customer-friendly servic...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - November 6, 2017 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health Local News CVS Source Type: news

Mylan misses sales, earnings estimate in Q3
Shares in Mylan (NSDQ:MYL) remained steady today after the pharmaceutical company missed expectations on Wall Street with its third quarter results. The Canonsburg, Penn.-based company posted profits of $88.3 million, or 16¢ per share, on sales of $2.99 billion for the 3 months ended Sept. 30, for bottom-line growth of 172% on sales loss of -2% compared with the same period last year. Get the full story at our sister site, Drug Delivery Business News. The post Mylan misses sales, earnings estimate in Q3 appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - November 6, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations MassDevice Earnings Roundup Pharmaceuticals Wall Street Beat Mylan Source Type: news

CVS Profits Hit By Narrow Networks As Aetna Deal Looms
CVS Health profits dipped in the third quarter the pharmacy chain continues to deal with the narrowing of insurer networks that exclude its pharmacies (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - November 6, 2017 Category: Pharmaceuticals Authors: Bruce Japsen, Contributor Tags: NASDAQ:WBA NYSE:CVS NYSE:AET Source Type: news

Cardinal Health logs fiscal Q1 sales miss, earnings beat, announces CEO succession
Cardinal Health (NYSE:CAH) today saw its fiscal first-quarter profits plunge on sales growth of nearly 2% and announced its plans for a CEO succession Dublin, Ohio-based Cardinal posted profits of $115 million, or 36¢ per share, on sales of $32.64 million for the three months ended Sept. 30, for a bottom-line decrease of -62.8% on sales growth of 1.9% compared with fiscal Q1 2017. Adjusted to exclude one-time items, earnings per share were $1.09, 9¢ ahead of the consensus forecast on Wall Street, where analysts were looking for sales of $33.48 billion. “Fiscal year 2018 started largely as we expected a...
Source: Mass Device - November 6, 2017 Category: Medical Devices Authors: Brad Perriello Tags: MassDevice Earnings Roundup Wall Street Beat Cardinal Health personnel-moves Source Type: news

Johnson & Johnson break ground on Chinese factory
Johnson & Johnson‘s (NYSE:JNJ) Ethicon subsidiary has broken ground on a new factory in China’s Jiangsu province, according to a report from China Daily. The new $180 million factory will produce devices including triclosan-coated sutures, endoscopic staplers and linear cutters, according to the report. The groundbreaking marks Johnson & Johnson’s first foray into producing minimally invasive and open surgical solutions in China, and is the 1st facility of its kind outside of the US, China Daily reports. The planned 60,521 square-foot facility will open in 2 phases, with the 1st operations beginni...
Source: Mass Device - November 3, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Surgical Ethicon johnsonandjohnson Source Type: news

Dentsply Sirona shares up on Q3 beat
Shares in Dentsply Sirona (NSDQ:XRAY) rose today after the medical device maker beat expectations on Wall Street with its 3rd quarter earnings release. The York, Penn.-based company posted profits of $90.5 million, or 39¢ per share, on sales of $1 billion for the 3 months ended September 30, seeing its bottom line shrink by 2% while its sales grew 5.8% compared with the same period during the previous year. After adjusting to exclude 1-time items, earnings per share were 70¢, well ahead of the 65¢ consensus on Wall Street, where analysts were expecting to see revenue of $981.7 million. “Our s...
Source: Mass Device - November 3, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News MassDevice Earnings Roundup Dentsply Sirona Source Type: news

Masimo crushes the Q3 earnings forecast, raises outlook
Masimo (NSDQ:MASI) this week reported third-quarter results that crushed the consensus earnings forecast and raised its sales and earnings outlook for the rest of the year, but share prices still fell on missed sales expectations. Irvine, Calif.-based Masimo posted profits of $39.2 million, or 70¢ per share, on sales of $181.3 million for the three months ended Sept. 30, for a bottom-line gain of 41.3% on sales growth of $13.1%. Analysts on Wall Street were looking for earnings of just 53¢ but sales of $188.6 million. Investors reacted by sending MASI shares down -2.6% to $85.46 apiece since the Oct. 31 earn...
Source: Mass Device - November 3, 2017 Category: Medical Devices Authors: Brad Perriello Tags: MassDevice Earnings Roundup Wall Street Beat Masimo Source Type: news

ConMed ticks up on Street-beating Q3 results
ConMed (NSDQ:CNMD) shares ticked up today after the medical device company yesterday reported third-quarter results that topped Wall Street’s forecast and announced the retirement of its financial chief. Utica, N.Y.-based ConMed posted profits of $7.2 million, or 26¢ per share, on sales of $190.1 million for the three months ended Sept. 30, for a -1.9% profit slide on sales growth of 2.9% compared with Q3 2016. Adjusted to exclude one-time items, earnings per share were 42¢, a penny ahead of The Street, where analysts were looking for sales of $187.1 million. “We are very pleased with our continued to...
Source: Mass Device - November 3, 2017 Category: Medical Devices Authors: Brad Perriello Tags: MassDevice Earnings Roundup Wall Street Beat ConMed Corp. Source Type: news

Intersect ENT beats Q3 sales estimates, raises full-year forecast
Shares in Intersect ENT (NSDQ:XENT) rose slightly today after the steroid-eluting implant maker beat sales expectations on Wall Street with its third quarter results. The Menlo Park, Calif.-based company posted a net loss of -$4.3 million on sales of $22.3 million for the 3 months ended Sept. 30, for sales growth of 21% compared with the same period last year. Get the full story at our sister site, Drug Delivery Business News. The post Intersect ENT beats Q3 sales estimates, raises full-year forecast appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - November 3, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Food & Drug Administration (FDA) Implants Otolaryngology Ear, Nose & Throat Pharmaceuticals Wall Street Beat intersectent Source Type: news

Hill-Rom ’ s Q4, 2017 earnings top estimates, sales miss
Hill-Rom Holdings (NYSE:HRC) shares came under pressure this morning after the medical device company reported fourth-quarter and full-year results that beat Wall Street’s consensus on earnings but missed its sales forecast. Chicago-based Hill-Rom posted profits of $69.4 million, or $1.03 per share, on sales of $643.5 million for the three months ended Sept. 30, for a bottom-line gain of 34.2% on sales growth of 5.0% compared with Q4 2016. Adjusted to exclude one-time items, earnings per share were $1.32, 4¢ ahead of The Street, but analysts there were looking for sales of $731.1 million. Full-year profits were ...
Source: Mass Device - November 3, 2017 Category: Medical Devices Authors: Brad Perriello Tags: MassDevice Earnings Roundup Wall Street Beat Hill-Rom Holdings Inc. Source Type: news

Insulet raises full-year sales forecast after Street-beating Q3
Shares in Insulet (NSDQ:PODD) soared today after the medical device maker topped sales expectations on Wall Street with its third quarter results. The Billerica, Mass-based company posted a net loss of -$2.2 million on sales of $121.8 million for the 3 months ended Sept. 30, for bottom-line growth of 38% on sales growth of 28% compared with the same period last year. Get the full story at our sister site, Drug Delivery Business News. The post Insulet raises full-year sales forecast after Street-beating Q3 appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - November 3, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Diabetes Drug-Device Combinations MassDevice Earnings Roundup Pharmaceuticals Wall Street Beat Insulet Source Type: news

Smith & Nephew takes $5m hit from hurricanes
Smith & Nephew (NYSE:SNN) said today that it took a $5 million hit during the third quarter from the hurricanes that devastated Texas and Puerto Rico and guided toward the low end of its outlook for the rest of the year. The British orthopedics and wound care giant, which only reports profit numbers at the middle and end of the year, said Q3 sales grew 2.9% to $1.15 billion compared with the same period last year. CEO Olivier Bohuon, who’s slated to step down at the end of the year, declined to comment on rumors about a possible takeover or sale of its divisions or about the Smith & Nephew stake taken by hedg...
Source: Mass Device - November 3, 2017 Category: Medical Devices Authors: Brad Perriello Tags: MassDevice Earnings Roundup Orthopedics Wall Street Beat Wound Care Smith & Nephew Source Type: news

Living with NASH: An Unexpected Diagnosis
As our waistlines thicken and our activity levels decrease, another chronic illness threatens to disturb our comfortable lifestyles. And, because it ’s relatively unknown, diagnosis comes as a shock to patients, who usually associate liver disease with heavy consumption of alcohol.Non-alcoholic steatohepatitis (NASH) is an advanced form of non-alcoholic fatty liver disease (NAFLD), where fat accumulates in the liver. It is most commonly associated with obesity, insulin resistance, metabolic syndrome and/or genetic polymorphisms, and is aggravated by inflammation and fibrosis.  First identified in the 1980s, its ...
Source: EyeForPharma - November 3, 2017 Category: Pharmaceuticals Authors: Mariel Metcalfe Source Type: news